Protagonist Therapeutics (PTGX) Long-Term Debt Issuances (2019 - 2023)

Protagonist Therapeutics has reported Long-Term Debt Issuances for 4 years, with the latest figure at $24.3 million in Q1 2023.

• Quarterly Long-Term Debt Issuances rose 66.99% year-over-year to $24.3 million in Q1 2023, while the trailing twelve-month figure through Dec 2023 was $24.3 million (up 66.99% YoY) and the FY2023 annual result came in at $24.3 million, up 66.99% from the prior year.
• Long-Term Debt Issuances advanced to $24.3 million in Q1 2023 per PTGX's latest filing, from $14.6 million in the prior quarter.
• Over five years, Long-Term Debt Issuances peaked at $34.0 million in Q3 2019 and troughed at -$24.7 million in Q4 2019.
• A 4-year average of $12.2 million and a median of $16.7 million in 2020 frame the typical range for Long-Term Debt Issuances.
• The widest YoY moves for Long-Term Debt Issuances: up 176.2% in 2020, down 81.23% in 2020.
• Over 4 years, Long-Term Debt Issuances stood at -$24.7 million in 2019, then jumped by 176.2% to $18.8 million in 2020, then decreased by 22.77% to $14.6 million in 2022, then jumped by 66.99% to $24.3 million in 2023.
• According to Business Quant data, Long-Term Debt Issuances over the past three periods registered $24.3 million, $14.6 million, and $18.8 million for Q1 2023, Q1 2022, and Q4 2020 respectively.